

1 Submitted to *JAMA Network Open* on: 25 February 2023

2 **Reduced control of SARS-CoV-2 infection is associated with lower mucosal**
3 **antibody responses in pregnant women**

4 Laura A. St Clair, PhD^{1#}; Raghda E. Eldesouki, PhD^{2,3#}, Jaiprasath Sachithanandham, PhD^{1#},
5 Anna Yin, MPH^{1#}, Amary Fall, PhD², C. Paul Morris, MD, PhD^{2,4}, Julie M. Norton, MS², Michael
6 Forman, PhD², Omar Abdullah, BS², Santosh Dhakal, DVM, PhD¹; Caelan Barranta, BS¹, Hana
7 Golding, PhD⁵, Susan J. Bersoff-Matcha, MD⁶, Catherine Pilgrim-Grayson⁷, Leah Berhane, MD,
8 MHA⁷, Andrea L. Cox, MD, PhD^{1,8,9}, Irina Burd, MD, PhD¹⁰, Andrew Pekosz, PhD^{1,8,11}, Heba H.
9 Mostafa, MD, PhD², Eili Y. Klein, PhD^{11,12*}, and Sabra L. Klein, PhD^{1,8*}

10 ¹ W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins
11 University Bloomberg School of Public Health, Baltimore, MD, USA

12 ²Department of Pathology, Division of Medical Microbiology, Johns Hopkins University School of
13 Medicine, Baltimore, MD, USA

14 ³Medical Genetics Unit, Histology Department, School of Medicine, Suez Canal University,
15 Egypt

16 ⁴National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda,
17 MD, USA

18 ⁵Division of Viral Products, Center of Biologics Evaluation and Research, U.S. Food and Drug
19 Administration, Silver Spring, MD, USA

20 ⁶Office of Women's Health, U.S. Food and Drug Administration, Silver Spring, MD, USA

21 ⁷Division of Urology, Obstetrics, and Gynecology; Office of Rare Diseases, Pediatrics, Urologic
22 and Reproductive Medicine; Office of New Drugs; Center for Drug Evaluation and Research;
23 U.S. Food and Drug Administration, Silver Spring, MD, USA

24 ⁸Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA

25 ⁹Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of
26 Medicine, Baltimore, MD, USA

27 ¹⁰Department of Obstetrics, Gynecology and Reproductive Sciences, University of Maryland
28 School of Medicine, Baltimore, MD, USA

29 ¹¹Department of Emergency Medicine, Johns Hopkins University School of Medicine, Baltimore,
30 MD, USA

31 ¹²Center for Disease Dynamics, Economics, and Policy, Washington DC, USA

32

33 #equal contributors

34 *co-senior authors

35 **Corresponding authors:**

36 eklein@jhu.edu

37 5801 Smith Ave, Davis Suite 3220, Baltimore, MD 21209

38 sklein2@jhu.edu (Primary)

39 615 North Wolfe Street, Rm W2118, Baltimore, MD 21205

40 **Running Title:** SARS-CoV-2 infection in pregnant women

41 **Key words:** COVID-19, gestation, breakthrough infection, Omicron variant, Delta variant

42

43 **Key Points**

44 **Question:** Is greater COVID-19 disease severity during pregnancy associated with either
45 reduced mucosal antibody responses to SARS-CoV-2 or increased viral RNA levels?

46 **Finding:** In a retrospective cohort of pregnant and non-pregnant women with confirmed SARS-
47 CoV-2 infection, we observed that (1) disease severity, including ICU admission, was greater
48 among pregnant than non-pregnant women; (2) vaccination was associated with reduced
49 recovery of infectious virus in non-pregnant women but not in pregnant women; (3) increased
50 nasopharyngeal viral RNA levels were associated with reduced mucosal IgG antibody
51 responses in pregnant women; and (4) greater maternal age was associated with reduced

52 mucosal IgG responses and increased viral RNA levels, especially among women infected with
53 the Omicron variant.

54 **Meaning:** The findings of this study provide novel evidence that, during pregnancy, lower
55 mucosal antibody responses are associated with reduced control of SARS-CoV-2, including
56 variants of concern, and greater disease severity, especially with increasing maternal age.
57 Reduced mucosal antibody responses among vaccinated pregnant women highlight the need
58 for bivalent booster doses during pregnancy.

59

60 **Abstract**

61 **Importance:** Pregnant women are at increased risk of severe COVID-19, but the contribution of
62 viral RNA load, the presence of infectious virus, and mucosal antibody responses remain
63 understudied.

64 **Objective:** To evaluate the association of COVID-19 outcomes following confirmed infection
65 with vaccination status, mucosal antibody responses, infectious virus recovery and viral RNA
66 levels in pregnant compared with non-pregnant women.

67 **Design:** A retrospective observational cohort study of remnant clinical specimens from SARS-
68 CoV-2 infected patients between October 2020-May 2022.

69 **Setting:** Five acute care hospitals within the Johns Hopkins Health System (JHHS) in the
70 Baltimore, MD-Washington, DC area.

71 **Participants:** Participants included confirmed SARS-CoV-2 infected pregnant women and
72 matched non-pregnant women (matching criteria included age, race/ethnicity, and vaccination
73 status).

74 **Exposure:** SARS-CoV-2 infection, with documentation of SARS-CoV-2 mRNA vaccination.

75 **Main Outcome(s):** The primary dependent measures were clinical COVID-19 outcomes,
76 infectious virus recovery, viral RNA levels, and mucosal anti-spike (S) IgG titers from upper
77 respiratory tract samples. Clinical outcomes were compared using odds ratios (OR), and

78 measures of virus and antibody were compared using either Fisher's exact test, two-way
79 ANOVA, or regression analyses. Results were stratified according to pregnancy, vaccination
80 status, maternal age, trimester of pregnancy, and infecting SARS-CoV-2 variant.

81 **Results(s):** A total of 452 individuals (117 pregnant and 335 non-pregnant) were included in the
82 study, with both vaccinated and unvaccinated individuals represented. Pregnant women were at
83 increased risk of hospitalization (OR = 4.2; CI = 2.0-8.6), ICU admittance, (OR = 4.5; CI = 1.2-
84 14.2), and of being placed on supplemental oxygen therapy (OR = 3.1; CI = 1.3-6.9). An age-
85 associated decrease in anti-S IgG titer and corresponding increase in viral RNA levels ($P <$
86 0.001) was observed in vaccinated pregnant, but not non-pregnant, women. Individuals in their
87 3rd trimester had higher anti-S IgG titers and lower viral RNA levels ($P <$ 0.05) than those in their
88 1st or 2nd trimesters. Pregnant individuals experiencing breakthrough infections due to the
89 omicron variant had reduced anti-S IgG compared to non-pregnant women ($P <$ 0.05).

90 **Conclusions and Relevance:** In this cohort study, vaccination status, maternal age, trimester
91 of pregnancy, and infecting SARS-CoV-2 variant were each identified as drivers of differences
92 in mucosal anti-S IgG responses in pregnant compared with non-pregnant women. Observed
93 increased severity of COVID-19 and reduced mucosal antibody responses particularly among
94 pregnant participants infected with the Omicron variant suggest that maintaining high levels of
95 SARS-CoV-2 immunity may be important for protection of this at-risk population.

96

97 **Introduction**

98 The ongoing COVID-19 pandemic has caused more than 650 million confirmed SARS-CoV-2
99 cases and greater than 6.6 million deaths reported worldwide [1]. Pregnant women are
100 classified as an at-risk group for severe complications, but the relationship between physiologic,
101 immunologic, and hormonal changes that occur during pregnancy and increased disease
102 severity risk remain unclear [2-4]. Analyses from the US Centers for Disease Control and
103 Prevention (CDC), show that among people with confirmed SARS-CoV-2 infections from

104 January 2020-December 2021, pregnant women were 5 times more likely to be admitted to an
105 intensive care unit (ICU), had a 76% greater risk of requiring invasive ventilation, and had a 3.3
106 times greater risk of death compared to non-pregnant women [5]. Despite these increased risks,
107 the immune responses to SARS-CoV-2 infection and efficacy of SARS-CoV-2 vaccination in
108 pregnant women remains understudied [6-10]. Studies that have analyzed immune responses
109 to SARS-CoV-2 infection and vaccination have largely focused on serological immunity, with
110 limited analysis of the mucosal antibody response to SARS-CoV-2 infection [11] and its
111 association with virus load, especially among pregnant women.

112 In this retrospective observational cohort study, remnant nasopharyngeal (NP) swab or
113 lateral mid-turbinate nasal swab samples from pregnant and matched non-pregnant patients
114 with confirmed positive SARS-CoV-2 infection who visited the Johns Hopkins Health System
115 between October 2020-May 2022 were analyzed for clinical outcomes, virus lineage, infectious
116 virus recovery, quantification of viral RNA level, and assessment of mucosal anti-spike (S) IgG
117 titers. Differences in each measure were compared between non-pregnant and pregnant
118 women and stratified by vaccination status, age, trimester of pregnancy, and infecting SARS-
119 CoV-2 variants.

120

121 **Materials and Methods**

122 **Ethical considerations and data availability**

123 This study was conducted under the Johns Hopkins University IRB protocols IRB00221396,
124 IRB00288258, IRB00289116 and a waiver of consent. Remnant clinical specimens from
125 individuals who tested positive for SARS-CoV-2 following standard of care or diagnostic
126 screening were used in this study. Whole viral genome sequencing was performed for genomic
127 SARS-CoV-2 surveillance and sequences were made publicly available in the GISAID
128 database.

129 **Subjects and sample selection**

130 This was a retrospective observational cohort study that used remnant nasopharyngeal swabs
131 (from symptomatic patients) or lateral mid-turbinate nasal swabs (from asymptomatic patients)
132 after standard of care diagnostic screening for SARS-CoV-2 infection across JHHS. Multiple
133 molecular assays were performed to confirm SARS-CoV-2 infection, as previously described
134 [12, 13]. Clinical information, and information about vaccination and immune status of
135 individuals were bulk extracted from the electronic health record that is shared across JHHS
136 and analyzed as previously described in [14]. The cohort excluded anyone who identified as
137 male, whose sex at birth was recorded as male, or who chose not to disclose their sex at birth.
138 Propensity score matching was used to select a cohort of control patients (3:1 ratio of control to
139 pregnant patients). Psmatch2 in Stata was used to match the patients on the variables listed
140 above using two methods, the first used no replacement (i.e., selection of best matches for
141 every pregnant patient in the cohort), then with a nearest neighbor of 4 with a caliper of 0.01
142 was used to select additional patients that might be near close matches. Initial selection
143 identified 287 pregnant patients and 817 matched non-pregnant controls; however, of this
144 group, complete vaccination data, full sequencing data, and remnant clinical specimens were
145 only available for 117 pregnant individuals (84 unvaccinated, 33 vaccinated), and 335 matched
146 non-pregnant controls (244 unvaccinated, 91 vaccinated) which defined the final cohort (**Table**
147 **1**). For the purposes of this study, vaccinated individuals were defined as those who either
148 received two primary doses (Pfizer/BioNTech or Moderna mRNA-1273 vaccines) or received
149 the primary doses and third booster dose prior to confirmed infection. Unvaccinated individuals
150 were defined as individuals who had received no COVID-19 vaccine prior to infection.
151 Individuals who were partially vaccinated were excluded from this study.

152 **Amplicon-based Sequencing**

153 Specimen preparation, extractions, and sequencing were performed as described previously
154 [15, 16]. NEBNext® ARTIC SARS-CoV-2 Companion Kit (VarSkip Short SARS-CoV-2 # E7660-
155 L) was used for library preparation and sequencing using the Nanopore GridION. Base-calling

156 of reads was conducted using the MinKNOW, followed by demultiplexing with guppybarcoder
157 that requires barcodes at both ends. Artic-ncov2019 medaka protocol was used for alignment
158 and variant calling [17, 18]. Clades were determined using Nextclade beta v 1.13.2
159 (clades.nextstrain.org, Last accessed March 30, 2022), and lineages were determined with
160 Pangolin COVID-19 lineage Assigner [19]. Sequences with coverage >90% and mean depth
161 >100 were submitted to GISAID database.

162 **SARS-CoV-2 PCR**

163 After clinical diagnosis, samples were retested using the CDC designed primers and probes for
164 the N gene to assess viral RNA levels (Cycle threshold, or Ct) [20]. Equivalent distribution of
165 data between samples collected from NP swabs and lateral mid-turbinate nasal swabs was
166 observed; as such, analysis of Ct values did not control for sample type.

167 **Infectious SARS-CoV-2 recovery**

168 TMPRSS2 VeroE6 cells (RRID: CVCL_YQ49) obtained from the cell repository of the National Institute
169 of Infectious Diseases, Japan [18, 21], and were cultured as previously described [22]. For virus
170 isolation, cells plated in 24-well dishes had the culture media replaced with 350 μ L of infection media
171 (culture media except that the FBS was reduced to 2.5%), followed by the addition of 150 μ L of swab
172 specimen. After incubation for 2 hours at 37°C, the inoculum was removed and replaced with 500 μ L
173 infection media. The cells were monitored daily for the appearance of SARS-CoV-2 cytopathic effect
174 (CPE) and the presence of SARS-CoV-2 genomes in CPE positive samples was confirmed by reverse
175 transcriptase PCR (RT-PCR) as previously described [23].

176 **Indirect enzyme-linked immunosorbent assays**

177 The protocol was adapted from published protocols [24] that were established previously in our
178 laboratory [6, 25-27], and was modified to assess total IgG from viral transport media (VTM).
179 Briefly, 96-well plates were coated with full-length vaccine-strain (ancestral) Spike (S) protein
180 (SeroNet) and incubated overnight at 4°C. Coating buffer was removed, plates were washed,
181 and blocked for 1 hour at room temperature. All samples were heat inactivated at 56°C for 1

182 hour prior to use. Negative controls using pooled VTM from COVID-19 negative patients were
183 plated at final concentration of 1:4. Positive control samples using a monoclonal antibody
184 against SARS-CoV-2 S protein (Sino Biological, 40150-D001) were plated at a final
185 concentration of 1:5000. Samples were prepared in 2-fold serial dilutions starting at 1:4 and
186 ending at 1:512. Blocking solution was removed, and diluted samples were added to the plates
187 and incubated at room temperature for 2 hours. Plates were washed 3 times, and 50 μ L of
188 secondary antibody (1:5000 dilution of HRP-conjugated goat anti-human Fc-specific IgG;
189 Invitrogen #A18823) was added to each well, and plates were incubated in the dark at room
190 temperature for 1 hour. Plates were washed and all residual liquid was removed. SIGMAFAST
191 OPD (o-phenylenediamine dihydrochloride) solution (Millipore Sigma) was added to each well,
192 and plates were incubated in the dark for 10 minutes. 3M HCl (ThermoFisher) was added to
193 each well to stop reaction, and the optical density of each plate was read at 490 nm using a
194 SpectraMax i3 ELISA Plate Reader (BioTek Instruments). Cutoff values were calculated by
195 adding the average of all negative control OD values and 3 times the standard deviation of the
196 negative control values. Values were considered positive (responders) if at or above the cutoff
197 value and negative (non-responders) if below the cutoff.

198

199 **Statistical analyses**

200 Comparisons of clinical characteristics, infectious virus recovery, and between anti-S IgG
201 responders and non-responders were tested using a two-sided Fisher's exact test. Prior to
202 conducting statistical analyses of anti-S IgG values, area under the curve (AUC) values were
203 calculated by plotting the normalized optical density values against the sample dilution. A two-
204 way ANOVA using Tukey's multiple comparisons was used to assess differences in anti-S IgG
205 AUC among groups, as well as differences in SARS-CoV-2 N Ct values among groups.
206 Multivariate regression models (logistic and linear) were used to investigate the association of
207 immunological measures (CPE, viral RNA level, and anti-Spike IgG) with pregnancy and

208 vaccination, controlling for participant age, race/ethnicity, and area deprivation index (ADI) as
209 necessary. An interaction term of the predictor variables was also included in the statistical
210 models to allow for the predicted probabilities to vary by pregnancy and vaccination status.
211 Contrasts of marginal effects were performed as post-estimation comparisons across pregnancy
212 and vaccination groups. All analyses were performed using either Prism software version 9.5
213 (Graphpad) or using Stata version 17.0 (StataCorp).

214

215 **Results**

216

217 **Clinical Data Analysis**

218 Clinical outcomes between pregnant and non-pregnant women with confirmed SARS-
219 CoV-2 infections differed. While pregnant women were less likely to report symptoms than non-
220 pregnant women (OR = 0.41; CI = 0.23-0.71; $P = 0.003$); among symptomatic individuals,
221 pregnant women were more likely to require hospitalization (OR = 4.2; CI = 2.0-8.6, $P = 0.0003$)
222 or be admitted to the ICU (OR = 4.5; CI = 1.2-14.2, $P = 0.02$) with COVID-19 as their primary
223 reason for admission (OR = 3.1; CI = 1.4-6.8; $P = 0.009$) (**Table 2**). In addition, pregnant women
224 were more likely to be placed on supplemental oxygen therapy than non-pregnant women (OR
225 = 3.1; CI = 1.3-6.9, $P = 0.012$) (**Table 2**).

226

227 **Distribution of SARS-CoV-2 variants among pregnant and non-pregnant women**

228 Whole genome sequencing (WGS) results were used to classify infecting SARS-CoV-2
229 variants into one of five categories: ancestral lineages (i.e., those circulating prior to Alpha),
230 Alpha variant, Delta variant, Omicron variant (through BA.2.12.1), and other (i.e., encompassing
231 all other variants). Among unvaccinated individuals, most samples collected were from
232 infections prior to vaccine availability and were predominately caused by ancestral lineages
233 (40% in non-pregnant women and 32% in pregnant women); samples from infections by all

234 other variants, however, were proportionally represented (**Table 3**). As emergency use
235 authorization of both the Pfizer/BioNTech and Moderna mRNA-1273 vaccines coincided with
236 the emergence and dominance of the Alpha variant, many samples collected from the
237 vaccinated non-pregnant and pregnant cohort were individuals experiencing breakthrough
238 infections from either the Delta variant (53% and 24%, respectively) or Omicron variants (38%
239 and 73%, respectively) (**Table 3**).

240

241 **SARS-CoV-2 virus RNA level and recovery of infectious virus from upper respiratory** 242 **samples**

243 To evaluate if the differences in clinical severity between non-pregnant and pregnant
244 women were due to differences in virus load, we compared infectious virus recovery and viral
245 RNA levels (Ct values) for each group. Because there were no statistical differences in the days
246 to symptom onset between symptomatic non-pregnant (2.2 ± 2.6 days) and pregnant (2.4 ± 3.4
247 days) women within this cohort, these analyses were conducted regardless of the days to
248 symptom onset and whether the patient was symptomatic or asymptomatic at the time of
249 collection, consistent with previous studies [17]. The number of samples from which infectious
250 virus was recovered was significantly lower among non-pregnant vaccinated than unvaccinated
251 women ($P < 0.05$; **Figure 1A**). While a similar trend was noted between unvaccinated and
252 vaccinated pregnant women, this did not reach statistical significance. There were no statistical
253 differences in the rates of infectious virus recovery between non-pregnant and pregnant women,
254 regardless of vaccination status. Viral RNA levels were similarly distributed between pregnant
255 and non-pregnant women, and no statistical differences were observed (**Figure 1B**).

256 Additionally, we assessed whether there were differences between the number of individuals
257 with high (Ct > 20; low viral RNA levels) versus low (Ct ≤ 20; high viral RNA levels) viral RNA
258 levels within each group. While greater percentages of vaccinated non-pregnant and pregnant
259 women had lower viral levels (58% and 60%, respectively) than their unvaccinated counterparts

260 (45% and 58%, respectively), these differences were not statistically significant (**Figure 1B, red**
261 **text**).

262

263 **Comparisons of mucosal anti-S IgG titers between pregnant and non-pregnant women**

264 Although previous reports suggest that pregnant women have reduced antibody
265 responses to SARS-CoV-2 infection [6, 28-30], these studies focused solely on serum antibody
266 responses. As SARS-CoV-2 infection initiates in the upper respiratory tract, we sought to
267 evaluate whether differences in mucosal IgG responses between non-pregnant and pregnant
268 women may account for differences in clinical severity. Vaccinated individuals had greater anti-
269 S IgG titers than unvaccinated individuals, regardless of pregnancy status ($P < 0.0001$; **Figure**
270 **1C**). Proportions of individuals with undetectable anti-S IgG (i.e., non-responders) were greater
271 in unvaccinated women compared to vaccinated women (non-pregnant: $P < 0.0001$; pregnant:
272 $P < 0.0001$), but there were no statistically significant differences between pregnant and non-
273 pregnant women within vaccination groups (**Figure 1C, red text**). The correlation between anti-
274 S IgG titers and infectious virus recovery and between anti-S IgG titers and viral RNA Ct values
275 was examined as a proxy to assess whether there were differences in the antiviral activity of
276 antibodies produced by non-pregnant and pregnant women. In the regression model controlling
277 for age, race/ethnicity, and ADI, there was a strong inverse correlation between anti-S IgG AUC
278 and the probability of recovering infectious virus (**Figure 1D**) as well as viral RNA level
279 (**Supplemental Figure 1A**) among unvaccinated women, regardless of pregnancy status, and
280 among vaccinated non-pregnant women. While similar inverse relationships were observed for
281 vaccinated pregnant women, they were not statistically significant. Notably, when the variable
282 for time post-symptom onset was included in the regression models (excluding asymptomatic
283 individuals; non-pregnant, N=35; pregnant, N=26), the inverse correlation between anti-S IgG
284 AUC and the probability of recovering infectious virus (**Supplemental Figure 1B**) as well as
285 between anti-S IgG and viral RNA Ct values (not shown) remained unchanged.

286

287 **Age and trimester of pregnancy influence mucosal immunity in pregnant, vaccinated**
288 **women**

289 To further interrogate possible pregnancy-associated differences in mucosal antibody
290 responses and viral level, we determined whether maternal age or gestational age contributed
291 to observed variability in SARS-CoV-2 anti-spike IgG AUC values (**Figure 1C**). Individuals in our
292 cohort were classified into one of three maternal age groups: ages 18-24, ages 25-34, and ages
293 35-44. We first compared viral RNA level, mucosal anti-S IgG AUC values, and rate of infectious
294 virus recovery regardless of days to symptom onset or whether the patients were symptomatic
295 or asymptomatic. Among unvaccinated individuals, viral RNA level (**Figure 2A**), rates of
296 infectious virus recovery (**Figure 2A, red text**), and mucosal anti-IgG AUC values (**Figure 2B**),
297 were similar across all groups, regardless of pregnancy status. No age-related differences were
298 noted in either viral RNA level (**Figure 2A**) or anti-S IgG AUC values (**Figure 2B**) among non-
299 pregnant, vaccinated women. Among vaccinated, pregnant women, viral RNA levels increased
300 (**Figure 2A**) and anti-S IgG AUC values decreased (**Figure 2B**) with maternal age, with
301 pregnant women ages 25-34 and ages 35-44 having significantly greater viral RNA ($P < 0.001$)
302 and lower anti-S IgG AUC values ($P < 0.001$) compared to pregnant women ages 18-24 (**Figure**
303 **2A-B**). Additionally, we observed trends in which the rates of infectious virus recovery
304 decreased with age in non-pregnant, vaccinated women, but increased with age in pregnant,
305 vaccinated women although these trends did not reach statistical significance (**Figure 2A, red**
306 **text**). The proportion of non-responders was greater in unvaccinated women compared to
307 vaccinated women, regardless of age (non-pregnant: $P < 0.0001$; pregnant: $P < 0.0001$), but
308 there were no statistically significant age-associated differences between pregnant and non-
309 pregnant women within vaccination groups (**Figure 2B, red text**). When controlled for
310 race/ethnicity and ADI, similar trends in the relationship between Ct values and age
311 (**Supplemental Figure 2A**) and with the probability of recovery of infectious virus and age

312 **(Supplemental Figure 2B)** within each group were observed, however, none were statistically
313 significant. Likewise, when controlled for race/ethnicity, ADI, and time since vaccination
314 **(Supplemental Figure 1C)**, we observed a similar age-associated trend of decreased anti-S
315 IgG AUC values among vaccinated pregnant women which was not statistically significant.
316 Importantly, the average time between completion of vaccination and infection was similar
317 among non-pregnant (176 ± 85 days) and pregnant (187 ± 95 days) women.

318 Next, we examined the relationships between gestational age, viral RNA level, mucosal
319 anti-S IgG AUC values, and recovery of infectious virus, regardless of days to symptom onset or
320 whether the patients were symptomatic or asymptomatic. Although no statistical differences in
321 viral RNA level **(Figure 2C)** or recovery of infectious virus **(Figure 2C, red text)** were observed
322 across trimesters of pregnancy, a trend of reduced viral level across trimester was observed,
323 with the lowest values being recorded in the third trimester for both unvaccinated and
324 vaccinated pregnant women. Among vaccinated pregnant women, anti-S IgG AUC values were
325 greater in the third trimester compared to either the first ($P < 0.05$) or second ($P < 0.05$)
326 trimester of pregnancy **(Figure 2D)**. Proportions of non-responders (i.e., those with
327 undetectable anti-S IgG) within each trimester were greater in unvaccinated compared to
328 vaccinated pregnant women (1st trimester: $P=0.0002$; 2nd trimester: $P=0.02$; 3rd trimester:
329 $P=0.002$); and were not statistically different between trimesters within vaccination groups
330 **(Figure 2D, red text)**. When controlled for race/ethnicity, ADI, and days post-symptom onset for
331 symptomatic individuals **(Supplemental Figure 2C)**, a similar trimester-associated decrease in
332 viral RNA level was observed, but this did not reach statistical significance. When controlled for
333 race/ethnicity, ADI, and time between completion of vaccination and infection **(Supplemental**
334 **Figure 1D)**, a trimester-associated increase in anti-S IgG was observed, but it was not
335 statistically significant. The mean time between completion of vaccination and infection was
336 similar between women in their first trimester (216 ± 57 days) and second trimester (214 ± 105
337 days) but decreased in women in their third trimester (159 ± 102 days) of pregnancy. Taken

338 together, these results suggest that mucosal antibody responses to SARS-CoV-2 infection are
339 reduced with increased maternal age and earlier in pregnancy.

340

341 **Pregnant women infected with Omicron variants have reduced mucosal anti-S IgG levels**

342 This patient cohort included individuals infected with both Delta and Omicron (through
343 BA.2.12.1) variants. We conducted an additional analysis of pregnancy-associated differences
344 based on the infecting variant. No differences in viral RNA level were detected among either
345 pregnant or non-pregnant women (**Figure 3A**). Pregnant, vaccinated individuals infected with
346 Omicron, but not Delta, variants had significantly lower anti-S IgG AUC values than non-
347 pregnant, vaccinated women ($P < 0.05$; **Figure 3B**). In contrast, anti-S IgG AUC values were
348 comparable between unvaccinated pregnant and non-pregnant women infected with either
349 Delta or Omicron variants. The proportion (**Figure 3B, red text**) of unvaccinated, non-pregnant
350 women with non-detectable anti-S IgG titers was lower among those infected with Omicron
351 variants compared to Delta ($P = 0.01$) but was higher among unvaccinated pregnant women (P
352 $= 0.0003$). Similar observations were made among vaccinated individuals but were not
353 statistically significant.

354 In our previous studies, we have shown that lower Ct values ($Ct \leq 20$; i.e., high viral RNA)
355 are associated with greater rates of infectious virus recovery [14, 17], and that individuals
356 infected with Delta variants had greater rates of infectious virus recovery than those infected
357 with Omicron variants [17]. Thus, we assessed whether there were differences in infectious
358 virus recovery among individuals with high viral RNA levels, but found no statistical differences
359 in the rates of infectious virus recovery between individuals infected with either the Delta or
360 Omicron variants within this cohort (**Supplemental Figure 2D**).

361

362 **Discussion**

363 The ongoing COVID-19 pandemic has raised awareness about pregnant women being
364 at greater risk for severe complications arising from many viruses, including SARS-CoV-2 [2, 5,
365 31]. In a retrospective cohort of pregnant and non-pregnant women with confirmed SARS-CoV-
366 2 infection, we observed that disease severity, including ICU admission and oxygen
367 supplementation, was greater among pregnant than non-pregnant women. We further explored
368 the role of vaccination in mucosal immunity and recovery of live SARS-CoV-2 and viral RNA
369 from the upper respiratory tract. Vaccination reduced recovery of infectious virus in non-
370 pregnant, but not pregnant, women suggesting that vaccine-induced immunity and protection
371 might be reduced during pregnancy, as previously reported for other infectious diseases [2].
372 Greater maternal age was associated with reduced mucosal antibody responses and greater
373 viral RNA levels, especially among pregnant women infected with the Omicron variant. These
374 findings provide mechanistic insights into how pregnant women are at greater risk of severe
375 COVID-19, including from breakthrough infections with variants of concern following receipt of
376 the monovalent COVID-19 vaccines.

377 Advanced maternal age (i.e., 35+ years of age) has previously been associated with
378 severe clinical outcomes and adverse fetal outcomes following SARS-CoV-2 in pregnant
379 women [32, 33]. While several studies highlight that SARS-CoV-2 infected pregnant women
380 typically present with asymptomatic or mild infections [3, 34], there are data illustrating that
381 pregnant women with SARS-CoV-2 infections are at increased risk of hospitalization, ICU
382 admittance, invasive ventilation, and death than non-pregnant women [3, 5, 31, 35]. Increased
383 risk of severe outcomes among pregnant women have persisted at least through the Delta
384 variant wave [5], and we now show that this further persists in the Omicron variant wave of the
385 pandemic.

386 Existing serological evidence in SARS-CoV-2 infection demonstrates that pregnant
387 women have enhanced inflammatory responses and reduced humoral responses compared to
388 non-pregnant women [6, 8, 36, 37]. The data from the current study add to the existing literature

389 by showing that mucosal antibody responses also are reduced in pregnant women compared
390 with non-pregnant women, with further reductions with advanced maternal age, in the first
391 trimester of pregnancy, and with some infecting variants of concern.

392 **Clinical Implications**

393 Among pregnant women with confirmed SARS-CoV-2 infection, reduced mucosal
394 antibody responses were associated with greater infectious virus recovery and viral RNA levels,
395 especially among women with advanced maternal age and women infected with the Omicron
396 variant. These data highlight that monovalent vaccines were not sufficient to protect pregnant
397 women against Omicron, which is consistent with reports in the general population [38-41], and
398 highlight the need for receipt of the bivalent booster in pregnant women. Pregnant women were
399 not included in phase III clinical trials for any of the vaccine candidates or the bivalent booster
400 [42]; and limited data are available from women who became pregnant while participating in
401 vaccine trials [43-46]. Because pregnancy is a unique biological state [47-51], additional studies
402 evaluating vaccine efficacy and the use of SARS-CoV-2 therapeutic agents (including use of
403 monoclonal antibodies) are necessary to ensure that the same correlates of protection apply to
404 this high-risk population [52]. Currently, the CDC recommends that pregnant women consult
405 with their physician to make decisions on vaccination. However, the lack of supporting vaccine
406 safety and efficacy in pregnancy complicates the benefit-risk analysis for healthcare providers
407 and pregnant women. Greater use of animal models to assess vaccine efficacy during
408 pregnancy and how pregnancy may alter vaccine-induced immunity and protection from
409 breakthrough infection is needed [42].

410 **Study Limitations**

411 The primary limitation of this study is the small sample size. While these studies were
412 powered for the primary clinical outcome, we were unable to give adequate statistical
413 consideration for additional potential confounding variables (e.g., time since symptom onset,
414 time between vaccination and sample collection) in the regression models. This was due both to

415 incomplete charting data (e.g. 77 symptomatic participants without a reported date of symptom
416 onset), and due to the use of convenience samples which limited our ability to control for
417 race/ethnicity, age, ADI, and time between vaccination and sample collection. When we applied
418 multivariate regression analysis that controlled for these variables, the trends in our data
419 remained consistent but lost statistical power. This highlights the need to verify these data in a
420 larger clinical cohort. Moreover, only upper respiratory samples were collected, and no serum
421 samples were available for additional analyses (e.g., IgA antibody levels, virus neutralization or
422 cross-reactivity with Spike proteins from variants of concern). For clinical outcomes, pregnant
423 women in our study were reportedly less symptomatic than non-pregnant women; this was,
424 however, based on self-reporting from a general list of questions that may not distinguish
425 COVID-19-related illness from pregnancy-associated symptoms (e.g., fatigue, muscles or body
426 aches, headache, digestive issues, nausea, or vomiting). Symptomatic COVID-19 cases among
427 pregnant women may not be accurately represented. Because samples were collected at
428 different points of care within the Johns Hopkins Medical System, differences in sample
429 collection may contribute to the variability in infectious virus recovery, viral RNA levels, and
430 antibody titers.

431 **Conclusions**

432 Pregnancy is associated with more severe outcomes from COVID-19 during the
433 Omicron wave of the pandemic. Advanced maternal age, first trimester of pregnancy, and
434 infection with Omicron were identified as factors contributing to decreased mucosal antibody
435 responses with concomitant increases in live virus recovery and mucosal viral RNA levels.
436 Greater consideration of pregnancy in prophylactic and therapeutic interventions for people
437 infected with SARS-CoV-2 [53] is needed to enable pregnant women and their healthcare
438 providers to make evidence-based decisions about care.

439

440 **Author Contributions:**

441 *Concept and Design:* LAS, REE, JS, ALC, IB, SLK, EYK, AP, HHM

442 *Acquisition, analysis, and interpretation of data:* LAS, REE, JS, AY, AF, CPM, JMN, MF, OA,

443 SD, CB, AP, HHM, EYK, SLK

444 *Drafting of Manuscript:* LAS, AY, SLK

445 *Critical revision of the manuscript for important intellectual content:* All authors.

446 *Statistical analysis:* LAS, AY, REE, JS

447 *Obtained Funding:* SLK, ALC, AP, HHM

448 *Supervision:* SLK, EYK, AP, HHM

449 **Acknowledgements:** We would like to sincerely thank Barbara Wesley, MD, MPH from the
450 Center for Drug Evaluation and Research at the U.S. Food and Drug Administration for her
451 thoughtful suggestions during conceptualization and design and during preparation of this
452 manuscript.

453 **Conflict of Interest Disclosures:** The authors have no conflicts of interest to disclose.

454 **Funding/Support:** This project was supported by the Food and Drug Administration (FDA) of
455 the U.S. Department of Health and Human Services (HHS) as part of a financial assistance
456 award [Center of Excellence in Regulatory Science and Innovation grant to Johns Hopkins
457 University, U01FD005942, awarded to SLK] funded by Office of Women's Health/FDA/HHS,
458 with additional support provided by NIH/NCI U54CA260492 (SLK and ALC); NIH/NIAID
459 N7593021C00045 (AP); 75D30121C11061 (HHM); U01CK000589 (EYK). The contents are
460 those of the author(s) and do not necessarily represent the official views of, nor an
461 endorsement, by Office of Women's Health/FDA/HHS, or the U.S. Government.

462

463 **Figure Legends**

464 **Figure 1 –SARS-CoV-2 viral RNA levels and antibody responses stratified by pregnancy**
465 **and vaccination status.** Remnant clinical upper respiratory tract specimens were used
466 determine rates of infectious virus recovery (A), viral RNA level (B), and anti-spike (ancestral

467 spike) IgG titers (C) from mucosal swab samples. In (A), a positive cytopathic effect (CPE) in
468 tissue culture was indicative of the presence of infectious virus. The *dashed line* in (B)
469 represents the cutoff value ($Ct \leq 20$) between high viral RNA and low viral levels, and the red text
470 indicates the percentage of participants with Ct values > 20 (low viral RNA levels). The *dashed*
471 *line* in (C) represents the limit of detection, and the red text indicates the percentage of non-
472 responders (results below the limit of detection). Multivariate logistic regression was used to
473 assess the correlation between anti-spike IgG titer and the probability of recovery of infectious
474 virus (D). Analysis included Fisher's exact test (A) and) and two-way ANOVAs with Tukey's
475 multiple comparisons test (B-C). * $P < 0.05$, *** $P < 0.001$, **** $P < 0.0001$. *anti-S IgG*, anti-
476 ancestral strain spike immunoglobulin G; *AUC*, area under the curve; *Ct*, cycle threshold;
477 SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

478

479 **Figure 2 – The effects of maternal and gestational age on mucosal viral RNA levels and**

480 **antibody responses (A-B)** Study participants were divided into three maternal age groups:

481 ages 18-24, ages 25-34, and ages 35-44, and samples were re-analyzed to assess differences

482 in viral RNA levels (A) and anti-S IgG (B). (C-D) Results from unvaccinated and vaccinated

483 pregnant women were stratified according to trimester of pregnancy and re-analyzed to assess

484 differences in viral RNA levels (C) and anti-S IgG (D). The red text in (A,C) indicates the

485 percentage of individuals with recoverable infectious virus, and the red text in (B,D) indicates

486 the percentage of non-responders (i.e. those with anti-S IgG below the limit of detection). (A-D):

487 Two-way ANOVA with Tukey's multiple comparisons test. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$,

488 **** $P < 0.0001$.

489 **Figure 3 – Analysis of mucosal viral RNA levels and antibody responses to Delta and**

490 **Omicron breakthrough infections during pregnancy.** Samples were classified according to

491 infecting strain (delta or omicron), pregnancy status, and vaccination status, and re-analyzed to

492 assess differences in viral RNA level (A) and anti-S (ancestral/vaccine strain) IgG (B). Two-way

493 ANOVA with Tukey's multiple comparisons tests (A-B) * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** P
494 < 0.0001 .

495 **Supplemental Figure 1 – Multivariate analysis of SARS-CoV-2 antibody responses.**

496 Multivariate logistic regression was used to assess the correlation between anti-spike IgG titer
497 and viral RNA levels (A), anti-spike IgG titer and the probability of infectious virus recovery (B),
498 anti-spike IgG titer and age (C), and trimester of pregnancy and anti-spike IgG titer (D). (A-C):
499 Variables were continuous, and p-values represent strength of correlation between variables for
500 each categorical group and comparisons between groups. (D): Trimester of pregnancy was
501 utilized as a categorical variable, p-values represent comparisons between stated groups.

502 **Supplemental Figure 2 – Multivariate analysis of SARS-CoV-2 viral RNA levels and
503 recovery of infectious virus.**

504 Multivariate logistic regression was used to assess the correlation between age and viral RNA
505 levels (A), age and the probability of infectious virus recovery (B), viral RNA levels and trimester
506 of pregnancy (C). Recovery of infectious virus from samples with high viral RNA levels ($Ct \leq 20$)
507 is reported in (D). (A-B) Variables were continuous, and p-values represent strength of
508 correlation between variables for each categorical group and comparisons between groups. (C):
509 Trimester of pregnancy was utilized as a categorical variable, p-values represent comparisons
510 between stated groups. (D): A Fisher's exact test was utilized.

511

512 **Tables**

513 **Table 1 – Patients and samples used in this study**

	Pregnant	<i>First Trimester</i>	<i>Second Trimester</i>	<i>Third Trimester</i>	Not Pregnant
Variables, N	117	28	36	53	335
Patient Age					
mean age	29.7	29.3	30.3	29.5	30.7
18-24, n (%)	26 (22.2%)	8 (28.6%)	7 (19.4%)	11 (20.8%)	72 (21.5%)
25-34, n (%)	64 (54.7%)	14 (50.0%)	18 (50.0%)	32 (60.4%)	157 (46.9%)
35-44, n (%)	27 (23.1%)	6 (21.4%)	11 (30.6%)	10 (18.9%)	106 (31.6%)
Race/Ethnicity					
Black, n (%)	48 (41.0%)	14 (50.0%)	13 (36.1%)	21 (39.6%)	138 (41.2%)
Hispanic, n (%)	22 (18.8%)	2 (7.1%)	6 (16.7%)	14 (26.4%)	53 (15.8%)
Other, n (%)	13 (11.1%)	4 (14.3%)	3 (8.3%)	6 (11.3%)	30 (9.0%)
White, n (%)	34 (29.1%)	8 (28.6%)	14 (38.9%)	12 (22.6%)	114 (34.0%)
9th Month, n (%)					
	26 (22.2%)	0 (0.0%)	0 (0.0%)	26 (49.1%)	0 (0.0%)
Area Deprivation Index					
	6.3	6.6	5.9	6.4	6.4
Charlson Score					
	0	0	0	0	0
Vaccination Status					
<i>Unvaccinated, n (%)</i>	84 (71.8%)	20 (71.4%)	27 (75.0%)	37 (69.8%)	244 (72.8%)
<i>Vaccinated, n (%)</i>	33 (28.2%)	8 (28.6%)	9 (25.0%)	16 (30.2%)	91 (27.2%)
Moderna mRNA-1273, n (%)	12 (10.2%)	2 (7.2%)	3 (8.3%)	7 (13.2%)	24 (7.2%)
Pfizer/BioNtech, n (%)	21 (18.0%)	6 (21.4%)	6 (16.7%)	9 (17.0%)	67 (20.0%)
Homologous Booster, n (%)	7 (6.0%)	2 (7.1%)	2 (5.6%)	3 (5.7%)	46 (13.7%)
Heterologous Booster, n (%)	1 (0.85%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	3 (0.90%)

"Vaccinated" includes individuals that received full two-dose mRNA vaccine regimen and/or received a booster dose prior to infection.

"Unvaccinated" includes individuals that had not received any vaccine dose prior to infection. Partially vaccinated individuals were excluded from this study.

514 **Table 2 - Differences in clinical severity between non-pregnant and pregnant females**
515

	Pregnant	<i>First Trimester</i>	<i>Second Trimester</i>	<i>Third Trimester</i>	Non-Pregnant	Odds Pregnant vs. Non-Pregnant Total [CI]	P-value
Variables, N	117	28	36	53	335		
Symptomatic Total, n (%)	91 (77.7%)	25 (89.3%)	32 (88.9%)	34 (64.1%)	300 (89.6%)	0.41 [0.23-0.71]	0.003
Unvaccinated, n (%)	63 (69.2%)	18 (72.0%)	24 (75.0%)	21 (61.8%)	220 (73.3%)	0.33 [0.17-0.61]	0.0014
Vaccinated, n (%)	28 (30.8%)	7 (28.0%)	8 (25.0%)	13 (38.2%)	80 (26.7%)	0.77 [0.26-2.1]	0.76
Hospitalization Total, n (%)	17 (14.5%)	0 (0.0%)	3 (8.3%)	14 (26.4%)	13 (3.9%)	4.2 [2.0-8.6]	0.0003
COVID reason for admission Total, n (%)	13 (11.1%)	0 (0.0%)	2 (5.6%)	11 (20.7%)	13 (3.9%)	3.1 [1.4-6.8]	0.009
ICU Admittance Total, n (%)	6 (5.1%)	0 (0.0%)	1 (2.8%)	5 (9.4%)	4 (1.2%)	4.5 [1.2-14.2]	0.02
Supplemental O2, n (%)	11 (9.4%)	0 (0.0%)	2 (5.6%)	9 (17.0%)	11 (3.3%)	3.1 [1.3-6.9]	0.012

516
517
518
519
520
521
522
523

Table 3 – SARS-CoV-2 Lineage Distribution

	Ancestral	Alpha	Delta	Omicron	Other	Total
Unvaccinated						
Non-pregnant, n (%)	97 (40%)	58 (24%)	32 (13%)	23 (9%)	34 (14%)	244
Pregnant, n (%)	27 (32%)	12 (14%)	14 (17%)	23 (27%)	8 (10%)	84
Vaccinated						
Non-pregnant, n (%)	5 (6%)	1 (1%)	48 (53%)	35 (38%)	2 (2%)	91
Pregnant, n (%)	0 (%)	0 (0%)	8 (24%)	24 (73%)	1 (3%)	33

524
525
526
527





References:

- 528 1. World Health Organization. *WHO Coronavirus (COVID-19) Dashboard*. 2022; Available from:
529 <https://covid19.who.int/>.



- 530 2. Vermillion, M.S. and S.L. Klein, *Pregnancy and infection: using disease pathogenesis to inform*
531 *vaccine strategy*. NPJ Vaccines, 2018. **3**: p. 6.
- 532 3. Allotey, J., et al., *Clinical manifestations, risk factors, and maternal and perinatal outcomes of*
533 *coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis*. Bmj, 2020.
534 **370**: p. m3320.
- 535 4. Yang, Z., et al., *Coronavirus disease 2019 (COVID-19) and pregnancy: a systematic review*. J
536 Matern Fetal Neonatal Med, 2022. **35**(8): p. 1619-1622.
- 537 5. Strid, P., et al., *Coronavirus Disease 2019 (COVID-19) Severity Among Women of Reproductive*
538 *Age With Symptomatic Laboratory-Confirmed Severe Acute Respiratory Syndrome Coronavirus 2*
539 *(SARS-CoV-2) Infection by Pregnancy Status-United States, 1 January 2020-25 December 2021*.
540 Clin Infect Dis, 2022. **75**(Supplement_2): p. S317-s325.
- 541 6. Sherer, M.L., et al., *Pregnancy alters interleukin-1 beta expression and antiviral antibody*
542 *responses during severe acute respiratory syndrome coronavirus 2 infection*. Am J Obstet
543 Gynecol, 2021. **225**(3): p. 301.e1-301.e14.
- 544 7. Collier, A.-R.Y., et al., *Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating*
545 *Women*. JAMA, 2021. **325**(23): p. 2370.
- 546 8. Collier, A.Y., et al., *Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating*
547 *Women*. Jama, 2021. **325**(23): p. 2370-2380.
- 548 9. Gray, K.J., et al., *Coronavirus disease 2019 vaccine response in pregnant and lactating women: a*
549 *cohort study*. Am J Obstet Gynecol, 2021. **225**(3): p. 303.e1-303.e17.
- 550 10. Edlow, A.G., et al., *Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental*
551 *Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic*.
552 JAMA Netw Open, 2020. **3**(12): p. e2030455.
- 553 11. Russell, M.W. and J. Mestecky, *Mucosal immunity: The missing link in comprehending SARS-CoV-*
554 *2 infection and transmission*. Front Immunol, 2022. **13**: p. 957107.
- 555 12. Mostafa, H.H., et al., *Comparison of the analytical sensitivity of seven commonly used*
556 *commercial SARS-CoV-2 automated molecular assays*. J Clin Virol, 2020. **130**: p. 104578.
- 557 13. Jarrett, J., et al., *Clinical performance of the GenMark Dx ePlex respiratory pathogen panels for*
558 *upper and lower respiratory tract infections*. J Clin Virol, 2021. **135**: p. 104737.
- 559 14. Huai Luo, C., et al., *Infection With the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-*
560 *CoV-2) Delta Variant Is Associated With Higher Recovery of Infectious Virus Compared to the*
561 *Alpha Variant in Both Unvaccinated and Vaccinated Individuals*. Clin Infect Dis, 2022. **75**(1): p.
562 e715-e725.
- 563 15. Thielen, P.M., et al., *Genomic diversity of SARS-CoV-2 during early introduction into the*
564 *Baltimore-Washington metropolitan area*. JCI Insight, 2021. **6**(6).
- 565 16. Morris, C.P., et al., *An Update on SARS-CoV-2 Diversity in the United States National Capital*
566 *Region: Evolution of Novel and Variants of Concern*. Clin Infect Dis, 2021.
- 567 17. Fall, A., et al., *The displacement of the SARS-CoV-2 variant Delta with Omicron: An investigation*
568 *of hospital admissions and upper respiratory viral loads*. EBioMedicine, 2022. **79**: p. 104008.
- 569 18. Morris, C.P., et al., *Omicron Subvariants: Clinical, Laboratory, and Cell Culture Characterization*.
570 Clin Infect Dis, 2022.
- 571 19. O'Toole, A., et al., *Assignment of epidemiological lineages in an emerging pandemic using the*
572 *pangolin tool*. Virus Evol, 2021. **7**(2): p. veab064.
- 573 20. Uhteg, K., et al., *Comparing the analytical performance of three SARS-CoV-2 molecular*
574 *diagnostic assays*. J Clin Virol, 2020. **127**: p. 104384.
- 575 21. Matsuyama, S., et al., *Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells*. Proc Natl
576 Acad Sci U S A, 2020. **117**(13): p. 7001-7003.

- 577 22. Gniazdowski, V., et al., *Repeat COVID-19 Molecular Testing: Correlation of SARS-CoV-2 Culture*
578 *with Molecular Assays and Cycle Thresholds*. Clin Infect Dis, 2020.
- 579 23. Lu, X., et al., *US CDC Real-Time Reverse Transcription PCR Panel for Detection of Severe Acute*
580 *Respiratory Syndrome Coronavirus 2*. Emerg Infect Dis, 2020. **26**(8): p. 1654-65.
- 581 24. Stadlbauer, D., et al., *SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a*
582 *Serological Assay, Antigen Production, and Test Setup*. Curr Protoc Microbiol, 2020. **57**(1): p.
583 e100.
- 584 25. Klein, S.L., et al., *Sex, age, and hospitalization drive antibody responses in a COVID-19*
585 *convalescent plasma donor population*. J Clin Invest, 2020. **130**(11): p. 6141-6150.
- 586 26. Park, H.S., et al., *Adaptive immune responses in vaccinated patients with symptomatic SARS-*
587 *CoV-2 Alpha infection*. JCI Insight, 2022. **7**(5).
- 588 27. Shapiro, J.R., et al., *Association of Frailty, Age, and Biological Sex With Severe Acute Respiratory*
589 *Syndrome Coronavirus 2 Messenger RNA Vaccine-Induced Immunity in Older Adults*. Clin Infect
590 Dis, 2022. **75**(Supplement_1): p. S61-s71.
- 591 28. Atyeo, C., et al., *COVID-19 mRNA vaccines drive differential antibody Fc-functional profiles in*
592 *pregnant, lactating, and nonpregnant women*. Sci Transl Med, 2021. **13**(617): p. eabi8631.
- 593 29. Wei, L., et al., *Clinical Characteristics and Outcomes of Childbearing-Age Women With COVID-19*
594 *in Wuhan: Retrospective, Single-Center Study*. J Med Internet Res, 2020. **22**(8): p. e19642.
- 595 30. Mohr-Sasson, A., et al., *Laboratory characteristics of pregnant compared to non-pregnant*
596 *women infected with SARS-CoV-2*. Arch Gynecol Obstet, 2020. **302**(3): p. 629-634.
- 597 31. US Centers for Disease Control and Prevention (CDC). *COVID-19 Underlying Medical Conditions*.
598 2022; Available from: [https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-](https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html)
599 [care/underlyingconditions.html](https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html).
- 600 32. Guarga Montori, M., et al., *Advanced maternal age and adverse pregnancy outcomes: A cohort*
601 *study*. Taiwan J Obstet Gynecol, 2021. **60**(1): p. 119-124.
- 602 33. Kortekaas, J.C., et al., *Risk of adverse pregnancy outcomes of late- and postterm pregnancies in*
603 *advanced maternal age: A national cohort study*. Acta Obstet Gynecol Scand, 2020. **99**(8): p.
604 1022-1030.
- 605 34. Vousden, N., et al., *The incidence, characteristics and outcomes of pregnant women hospitalized*
606 *with symptomatic and asymptomatic SARS-CoV-2 infection in the UK from March to September*
607 *2020: A national cohort study using the UK Obstetric Surveillance System (UKOSS)*. PLoS One,
608 2021. **16**(5): p. e0251123.
- 609 35. Bellos, I., A. Pandita, and R. Panza, *Maternal and perinatal outcomes in pregnant women*
610 *infected by SARS-CoV-2: A meta-analysis*. Eur J Obstet Gynecol Reprod Biol, 2021. **256**: p. 194-
611 204.
- 612 36. Lokken, E.M., et al., *Disease severity, pregnancy outcomes, and maternal deaths among*
613 *pregnant patients with severe acute respiratory syndrome coronavirus 2 infection in Washington*
614 *State*. Am J Obstet Gynecol, 2021. **225**(1): p. 77.e1-77.e14.
- 615 37. Xu, S., et al., *Clinical Manifestation and Neonatal Outcomes of Pregnant Patients With*
616 *Coronavirus Disease 2019 Pneumonia in Wuhan, China*. Open Forum Infect Dis, 2020. **7**(7): p.
617 ofaa283.
- 618 38. Surie, D., et al., *Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated*
619 *Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant*
620 *Periods of SARS-CoV-2 Omicron Variant in the United States - IVY Network, 18 States, December*
621 *26, 2021-August 31, 2022*. MMWR Morb Mortal Wkly Rep, 2022. **71**(42): p. 1327-1334.
- 622 39. Andrews, N., et al., *Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant*. N
623 Engl J Med, 2022. **386**(16): p. 1532-1546.


- 624 40. Link-Gelles, R., et al., *Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-*
625 *CoV-2 Infection - Increasing Community Access to Testing Program, United States, September-*
626 *November 2022*. MMWR Morb Mortal Wkly Rep, 2022. **71**(48): p. 1526-1530.
- 627 41. Planas, D., et al., *Considerable escape of SARS-CoV-2 Omicron to antibody neutralization*. Nature,
628 2022. **602**(7898): p. 671-675.
- 629 42. Klein, S.L., P.S. Creisher, and I. Burd, *COVID-19 vaccine testing in pregnant females is necessary*. J
630 Clin Invest, 2021. **131**(5).
- 631 43. Food and Drug Administration, *Vaccines and Related Products Advisory Committee Meeting June*
632 *7, 2022*.
- 633 44. Food and Drug Administration, *Vaccines and Related Biological Products Advisory Committee*
634 *Meeting*. December 10, 2020.
- 635 45. Food and Drug Administration, *Vaccines and Related Biological Products Advisory Committee*
636 *Meeting*. February 26, 2021.
- 637 46. Food and Drug Administration, *Vaccines and Related Biological Products Advisory Committee*
638 *Meeting*. October 14-15, 2021.
- 639 47. Bohn, M.K. and K. Adeli, *Physiological and metabolic adaptations in pregnancy: importance of*
640 *trimester-specific reference intervals to investigate maternal health and complications*. Crit Rev
641 Clin Lab Sci, 2022. **59**(2): p. 76-92.
- 642 48. Mor, G. and I. Cardenas, *The immune system in pregnancy: a unique complexity*. Am J Reprod
643 Immunol, 2010. **63**(6): p. 425-33.
- 644 49. Soma-Pillay, P., et al., *Physiological changes in pregnancy*. Cardiovasc J Afr, 2016. **27**(2): p. 89-94.
- 645 50. Robinson, D.P. and S.L. Klein, *Pregnancy and pregnancy-associated hormones alter immune*
646 *responses and disease pathogenesis*. Horm Behav, 2012. **62**(3): p. 263-71.
- 647 51. Mauvais-Jarvis, F., S.L. Klein, and E.R. Levin, *Estradiol, Progesterone, Immunomodulation, and*
648 *COVID-19 Outcomes*. Endocrinology, 2020. **161**(9).
- 649 52. Food and Drug Administration, *Pregnant Women: Scientific and Ethical Considerations for*
650 *Inclusion in Clinical Trials Guidance for Industry*. 2018: Rockville, MD. p. 14.
- 651 53. Garneau, W.M., et al., *Analysis of Clinical Outcomes of Pregnant Patients Treated With*
652 *Nirmatrelvir and Ritonavir for Acute SARS-CoV-2 Infection*. JAMA Netw Open, 2022. **5**(11): p.
653 e2244141.
- 654




A




B



D



A



B

